Skip to main content
. 2017 Dec 19;86(1):e00486-17. doi: 10.1128/IAI.00486-17

FIG 2.

FIG 2

Modification of the PfMSP8 domain does not affect the immunogenicity of rPfMSP1/8(CΔS) relative to the original rPfMSP1/8 antigen. CB6F1/J mice (5/group) were immunized three times with 10 μg/dose of rPfMSP1/8 (black bars) or rPfMSP1/8(CΔS) (gray bars) formulated with Quil A (A) or Montanide plus CpG ODN (B) as an adjuvant. Sera collected following the final immunization were analyzed for antigen-specific IgG titers (means ± standard deviations) by an ELISA using plates coated with rPfMSP1/8, rPfMSP8, GST-PfMSP119(FVO), or GST-PfMSP119(3D7) antigens. ns, nonsignificant (P > 0.05).